

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A method for the ~~prevention or~~ treatment of retinopathy which comprises administering to a mammal in need of such ~~prevention or~~ treatment, but not having macular edema, an amount of a carbonic anhydrase inhibitor sufficient to ~~prevent or~~ treat retinopathy.
2. (Original) A method according to Claim 1, wherein the retinopathy comprises diabetic retinopathy.
3. (Original) A method according to Claim 2, wherein the diabetic retinopathy comprises non-proliferative diabetic retinopathy.
4. (Canceled)
5. (Currently Amended) A method according to Claim 2, wherein the diabetic retinopathy comprises preproliferative ~~or proliferative~~ diabetic retinopathy.

6. (Currently Amended) A method according to Claim 2 for ~~the prevention~~ slowing the progression of diabetic retinopathy in a diabetic not suffering from diabetic retinopathy which comprises administering to said diabetic an amount of a carbonic anhydrase inhibitor sufficient to ~~prevent~~ slow the progression of diabetic retinopathy.

7. (Original) A method according to Claim 1, wherein the retinopathy comprises a vascular retinopathy.

8. (Original) A method according to Claim 7, wherein the vascular retinopathy comprises branch retinal vein occlusion.

9. (Original) A method according to Claim 7, wherein the vascular retinopathy comprises central retinal vein occlusion.

10. (Original) A method according to Claim 7, wherein the vascular retinopathy comprises sickle cell retinopathy.

11. (Original) A method according to Claim 7, wherein the vascular retinopathy comprises capillary occlusion or ischemia.

1
B
confid

12. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is administered ophthalmically to the eye or eyes.

13. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is administered systemically.

14. (Original) A method according to Claim 13, wherein the carbonic anhydrase inhibitor is administered orally.

15. (Original) A method according to Claim 13, wherein the carbonic anhydrase inhibitor is administered parenterally.

16. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is dorzolamide.

17. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is acetazolamide.

18. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is brinzolamide.

19. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is methazolamide.

20. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is ethoxzolamide.

21. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is butazolamide.

22. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is dichlorphenamide.

23. (Original) A method according to Claim 1, wherein the carbonic anhydrase inhibitor is flumethiazide.

24. (Original) A method according to Claim 12, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

25. (Original) A method according to Claim 14, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

26. (Original) A method according to Claim 15, wherein the carbonic anhydrase inhibitor is dorzolamide or brinzolamide.

27. (New) A method for the treatment of retinopathy which comprises administering to a mammal in need of such treatment, but not having macular edema, an amount of a carbonic anhydrase inhibitor sufficient to treat retinopathy, said carbonic anhydrase inhibitor being the sole active agent administered to treat retinopathy.

28. (New) A method according to Claim 27, wherein the retinopathy comprises diabetic retinopathy.

29. (New) A method according to Claim 28, wherein the diabetic retinopathy comprises non-proliferative diabetic retinopathy.

30. (New) A method according to Claim 28, wherein the diabetic retinopathy comprises preproliferative diabetic retinopathy.

31. (New) A method according to Claim 28 for slowing the progression of diabetic retinopathy in a diabetic not suffering from diabetic retinopathy which comprises administering to said diabetic an amount of a carbonic anhydrase inhibitor sufficient to slow the progression of diabetic retinopathy.

32. (New) A method according to Claim 27, wherein the retinopathy comprises a vascular retinopathy.

33. (New) A method according to Claim 32, wherein the vascular retinopathy comprises branch retinal vein occlusion.

34. (New) A method according to Claim 32, wherein the vascular retinopathy comprises central retinal vein occlusion.

35. (New) A method according to Claim 32, wherein the vascular retinopathy comprises sickle cell retinopathy.

36. (New) A method according to Claim 32, wherein the vascular retinopathy comprises capillary occlusion or ischemia.

37. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is administered ophthalmically to the eye or eyes.

38. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is administered systemically.

39. (New) A method according to Claim 38, wherein the carbonic anhydrase inhibitor is administered orally.

40. (New) A method according to Claim 38, wherein the carbonic anhydrase inhibitor is administered parenterally.

41. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is dorzolamide.

42. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is acetazolamide.

43. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is brinzolamide.

44. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is methazolamide.

45. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is ethoxzolamide.

46. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is butazolamide.

47. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is dichlorphenamide.

48. (New) A method according to Claim 27, wherein the carbonic anhydrase inhibitor is flumethiazide.

49. (New) A method according to Claim 37, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

50. (New) A method according to Claim 39, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

B
contd

Attorney's Docket No. 032904-001

Application No. 09/925,659

Page 10

31
could 51. (New) A method according to Claim 40, wherein the carbonic anhydrase inhibitor is dorzolamide or brinzolamide.
